David H Fitchett

5PUBLICATIONS
12CO-AUTHORS
Econometric and statistical methodsEpidemiological modellingNutritional epidemiologyMolecular medicine
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Aug 31, 2021
Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the EMPA-REG OUTCOME trial.

Muthiah Vaduganathan, Silvio E Inzucchi, Naveed Sattar

|Apr 01, 2020
Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart Failure in Diabetes categories: Post hoc analysis of the EMPA-REG OUTCOME trial.

Subodh Verma, Abhinav Sharma, Bernard Zinman

|Mar 03, 2020
Can the cardiovascular risk reductions observed with empagliflozin in the EMPA-REG OUTCOME trial be explained by concomitant changes seen in conventional cardiovascular risk factor levels?

Ruth L Coleman, Alastair M Gray, Uli C Broedl Md

|Feb 08, 2020
Association between uric acid levels and cardio-renal outcomes and death in patients with type 2 diabetes: A subanalysis of EMPA-REG OUTCOME.

Subodh Verma, Qiuhe Ji, Deepak L Bhatt

|May 14, 2019
A safety update on sodium glucose co-transporter 2 inhibitors.

David Fitchett

Pageof 1

Frequent Collaborators

4 joint publications

Bernard Zinman

2 joint publications

Subodh Verma

2 joint publications

Anne Pernille Ofstad

1 joint publications

Qiuhe Ji